BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...costly Phase III trials comes shortly after liraglutide...
...that ELAD failed on the primary endpoint.” While liraglutide...
...masipro) Victoza (Brand), NN2211 (Compound #), liraglutide (Generic), Victoza...
BioCentury | May 13, 2020
Product Development

Phase III obesity data show Novo’s semaglutide nearing threshold to replace gastric bypass surgery

...Novo announced Phase III data on Wednesday that sets up semaglutide to replace its Saxenda liraglutide...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

...commercial growth for an obesity therapeutic, Novo already has a footprint in the market. Saxenda liraglutide...
...as a once-daily high-dose formulation. It is also marketed at a lower dose as Victoza liraglutide...
BioCentury | Nov 16, 2019
Company News

Nov. 15 Company Quick Takes: Qiagen continues climb after confirming takeout offers; plus Fetroja, selumetinib, PharmAbcine, semaglutide

...council voted that the long-acting GLP-1 analog did not meet that threshold compared with Victoza liraglutide...
BioCentury | Sep 20, 2019
Company News

Approval of Novo’s Rybelsus gives diabetes patients first oral option in GLP-1R class

...NN9535 (Compound #), subcutaneous semaglutide (Informal) GLP-1Fc, Trulicity, dulaglutide (LY2189265) Victoza (Brand), NN2211 (Compound #), liraglutide (Generic), Victoza...
BioCentury | Jun 11, 2019
Clinical News

June 10 Clinical Quick Takes: Oral semaglutide superior to Jardiance, non-inferior to Victoza; plus Aptinyx and Eli Lilly

...4, the therapy met the primary endpoint of non-inferiority to Novo’s long-acting GLP-1 analog Victoza liraglutide...
...Associate Editor Humalog insulin lispro Jardiance, empagliflozin (BI-10773) NYX-2925 oral semaglutide (NN9924, OG217SC) Victoza (Brand), NN2211 (Compound #), liraglutide (Generic), Victoza...
BioCentury | May 3, 2019
Company News

May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ

...million) for the quarter. That beat analyst expectations of DKK1.28 billion. Sales of once-daily Victoza liraglutide...
BioCentury | Mar 13, 2019
Distillery Therapeutics

A PYY-IgG conjugate for obesity

...model of obesity, the conjugate decreased food intake and body weight, and the conjugate plus liraglutide...
...conjugate in additional models of obesity. Novo Nordisk A/S has the glucagon-like peptide-1 (GLP-1) analog liraglutide...
...Spring House, Pa. e-mail: srangwal@its.jnj.com CONTACT: James N. Leonard, same affiliation as above e-mail: jleonar7@its.jnj.com Hongjiang Li liraglutide...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Endocrine/metabolic

...non-neutralizing control mAb. And in the same model, the mAb plus the GLP-1R agonists Victoza liraglutide...
...includes Phase I testing of the mAb (AMG 598) in obesity. Novo Nordisk A/S markets Victoza...
...email: dlloyd@amgen.com Claire Quang Byetta, exenatide (AC2993, Exendin-4) GLP-1Fc, Trulicity, dulaglutide (LY2189265) Victoza (Brand), NN2211 (Compound #), liraglutide (Generic), Victoza...
BioCentury | Nov 9, 2018
Product Development

Cashing out CVOT

...of MACEs in CVOTs: SGLT2 inhibitors Jardiance empagliflozin and Invokana canagliflozin, and GLP-1 agonist Victoza liraglutide...
...partners Boehringer Ingelheim GmbH and Eli Lilly and Co., Invokana by Johnson & Johnson and Victoza...
Items per page:
1 - 10 of 381